Annotation Detail
Information
- Associated Genes
- SMARCA4
- Associated Variants
-
SMARCA4 UNDEREXPRESSION
SMARCA4 UNDEREXPRESSION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treated with adjuvant cisplatin/vinorelbine (n=36) (HR=0.1, 95% CI: 0.0-0.5, P=0.002 [low]; HR 1.0, 95% CI: 0.5-2.3, P=0.92 [high]) compared to patients in the observation arm (N=30).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/837
- Gene URL
- https://civic.genome.wustl.edu/links/genes/78
- Variant URL
- https://civic.genome.wustl.edu/links/variants/349
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Cisplatin,Vinorelbine
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26671993
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cisplatin | Sensitivity | true |
| Vinorelbine | Sensitivity | true |